Welcome to our dedicated page for Arteris SEC filings (Ticker: AIP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading Arteris, Inc.'s SEC filings can feel like navigating a dense wiring diagram—hundreds of pages on deferred royalties, automotive safety certifications, and stock-based compensation. If you need the revenue backlog buried in a 10-K or want to spot Form 4 trades before the next design-win press release, the traditional EDGAR search simply takes too long.
Stock Titan solves this problem. Our AI-powered summaries translate complex semiconductor accounting into plain language, flagging key metrics such as licensing revenue mix, R&D capitalization trends, and customer concentration. Real-time alerts pull every Arteris quarterly earnings report 10-Q filing, 8-K material events explained in minutes, and Arteris insider trading Form 4 transactions as they post—so you never miss a disclosure.
Here’s what you can uncover instantly:
- Arteris annual report 10-K simplified—royalty schedules, risk factors, and segment performance distilled within seconds.
- Arteris Form 4 insider transactions real-time—track executive stock sales or option exercises alongside AI context on upcoming product milestones.
- Proxy statement executive compensation—see how design-win milestones affect equity awards without combing through tables.
- Arteris earnings report filing analysis—compare quarter-over-quarter gross margin shifts and R&D intensity.
Whether you’re monitoring executive stock transactions, assessing patent litigation exposure, or just trying to understand Arteris SEC filings explained simply, our platform surfaces the data professionals rely on—no jargon, no delays.
Arteris, Inc. (AIP) – Form 4 insider transaction
Director S. Atiq Raza reported a sale of 1,136 common shares on 18-Jul-2025 at a reported price of $10.00 per share. The disposition was executed under a previously adopted Rule 10b5-1 trading plan dated 6-Jun-2024.
Following the sale, Raza continues to hold a large position: 682,662 shares held indirectly through the Saiyed Atiq Raza & Nandini Saraiya 2012 Revocable Trust and 20,839 shares held directly. The transaction reduced his total ownership by roughly 0.16%, indicating only a marginal change in economic exposure while maintaining significant alignment with shareholders.
Arteris, Inc. (AIP) – Form 4 insider filing
Director Joachim Kunkel reported the acquisition of 1,727 fully-vested restricted shares of Arteris common stock on 07/05/2025. The shares represent board retainer fees that Mr. Kunkel chose to receive in stock rather than cash; the filing states the director also elected to defer receipt of these shares. The transaction was recorded at a price of $0.00 because it is compensation-related, not an open-market purchase. Following the award, Mr. Kunkel’s direct ownership increases to 66,322 shares. No derivative security activity was reported.
The filing indicates Mr. Kunkel remains classified as a Director and files individually. No amendments or additional reporting persons are noted.
While the award is modest in size, insider share accumulation—especially when taken in lieu of cash—may signal greater alignment with shareholder interests. However, because it is routine compensation rather than a discretionary market purchase, the market impact is likely limited.
FAQ
What is the current stock price of Arteris (AIP)?
What is the market cap of Arteris (AIP)?
